Paysign (PAYS) Earnings Date & Reports

Key Takeaways

• Paysign reported record third quarter 2026 revenue of $30.8 million, up 42.6% year over year.
• GAAP (Generally Accepted Accounting Principles) net income reached $6.7 million, or $0.11 per diluted share, beating the $0.09 consensus estimate.
• Operating margin more than tripled to 23.8%, up from 7.3% in the prior-year quarter.
• Pharma (patient affordability) revenue surged 109.8% to $16.6 million, while plasma revenue rose 7.5% to $13.8 million.
• Management raised its full-year projections on key metrics, expecting to exit 2026 with 190–195 active patient affordability programs.
• For more on the company's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
• Discover Trending AI Robots to see how automated trading strategies are navigating current market conditions.

Earnings Context and Why It Matters

Paysign sits at the intersection of fintech and healthcare, providing payment processing, patient affordability programs, and donor compensation solutions for the plasma, pharmaceutical, and life sciences industries. Its third quarter 2026 report matters because it tests whether the company's patient affordability business can keep powering outsized growth while the legacy plasma segment faces a center-consolidation transition. Prior quarters showed rapidly expanding margins and a mix shift toward higher-margin pharma revenue, and investors were watching closely to see whether that operating leverage could persist. With plasma center counts expected to decline into year-end, the durability of pharma momentum has become the central question for the stock.

Reported Results

Paysign posted record third quarter 2026 revenue of $30.8 million, up 42.6% from $21.6 million a year earlier and above the $29.02 million consensus estimate. Pharma industry revenue was the standout, climbing 109.8% year over year to $16.6 million, driven by continued program expansion — the company launched 62 net new patient affordability programs over the trailing 12 months and exited the quarter with 167 active programs. Plasma revenue rose 7.5% to $13.8 million, helped by stronger per-center utilization.

Profitability improved sharply. Gross margin expanded to 64.7% from 56.3%, and operating margin more than tripled to 23.8%, an improvement of 1,650 basis points. GAAP net income totaled $6.7 million, or $0.11 per fully diluted share, up from $2.2 million, or $0.04 per share, a year ago — beating the $0.09 consensus EPS (earnings per share) estimate. Revenue, operating margin, and net income all finished above the high end of management's guidance.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to uncover potential opportunities aligned with your own strategy.

Market Reaction and Investor Sentiment

Heading into the print, sentiment around Paysign was positive, supported by a strong second quarter that saw the company raise its full-year outlook and a stock that had gained substantially over the prior 12 months. The third quarter's top- and bottom-line beats, combined with another step-up in profitability, reinforced confidence in the company's operating leverage story. At the same time, investors remain attuned to the planned reduction in plasma centers — management expects to end 2026 with 445–450 centers versus 562 at the end of the third quarter — which represents a transitional headwind even as pharma growth accelerates.

Forward Outlook and Key Factors to Monitor

Following this report, investors should watch how Paysign's guidance evolves for the remainder of 2026. Management raised full-year projections on key metrics and expects to exit the year with 190–195 active patient affordability programs, signaling that pharma momentum is expected to continue offsetting plasma-center consolidation.

Operating leverage (the ability to grow profit faster than revenue as fixed costs spread across a larger base) remains a central theme. With gross margin now above 64% and operating margin at 23.8%, the question is whether the company can sustain these levels as its mix continues shifting toward higher-margin pharma revenue.

Other factors worth monitoring include the company's donor management software platform, which remains under regulatory review and could open a new long-term growth avenue if approved, as well as the company's early international expansion efforts. Balance sheet strength — including a growing cash position and zero bank debt — provides flexibility for continued investment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations